Neuro-Oncology News

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.

Rivaroxaban significantly reduced venous thromboembolism recurrence among patients who had cancer and VTE compared with dalteparin, according to findings published in Journal of Clinical Oncology.

An intratumoral infusion of recombinant nonpathogenic polio-rhinovirus chimera appeared safe and prolonged survival among patients with stage IV malignant glioma, according to phase 1 study results published in The New England Journal of Medicine.

Thirty-one percent of adult survivors of childhood cancer reported a lack of concern for future health and 40% reported a lack of concern regarding risk for future cancer, according to study findings.

CHICAGO — Sophia Randolph, MD, PhD, chief medical officer at Alexo Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about ALX148.

CHICAGO — Scott Z. Fields, MD, senior vice president and head of pharmaceutical development for oncology at Bayer, spoke with HemOnc Today at ASCO Annual Meeting about key company data presented at the meeting.

Although a risk assessment tool can identify patients with cancer who are at risk for hepatitis B virus (HBV) reactivation from anticancer therapy, most patients will still require HBV testing, according to study results.

CHICAGO — Andrew Coop, vice president of U.S. medical affairs for oncology at AstraZeneca, spoke with HemOnc Today at ASCO Annual Meeting about advances in the company’s oncology portfolio.

The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.

CHICAGO — Michael Ciesielski, PhD, assistant professor in the department of neurosurgery at Roswell Park Comprehensive Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about SurVaxM.